Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. sophomore Avg
|
New words:
abreast, accusing, alleging, amicably, assistance, attempting, automatic, back, Barandnic, brand, capability, care, CECL, classified, compete, conversion, defendant, demonstrate, disadvantage, discovery, dramatically, drop, eighteen, enjoy, equal, European, expertise, extinguishment, foreign, greater, healthcare, human, inconsistent, justification, large, LB, lesser, licensee, marketplace, matter, medical, medicinal, methodology, negotiate, negotiating, obsolete, owe, pace, pending, percent, physician, placement, portion, purpose, rapid, Regulation, rendered, son, study, submission, successfully, track, transparency, unpaid, void
Removed:
advertising, aggregate, AVERSAI, AVERSAL, Barandic, cessation, chain, Channel, commenced, comparison, conclusion, continued, country, declared, depending, disease, disrupt, economic, emerged, exposed, federal, fee, fifteen, filled, government, governmental, home, imposed, infection, IRS, length, local, magnitude, main, manner, MDM, media, negatively, ninety, noted, occur, offset, outbreak, pandemic, people, perception, physical, present, productivity, prohibit, project, proscribing, quarantining, reception, recipient, residence, resulted, return, scope, settlement, shelter, spread, stay, subsequently, travel, world, Worldwide
Financial report summary
?Management Discussion
- For the three months ended April 30, 2024, we generated revenue of $408,532 and our costs of revenue were $243,746. For the three months ended April 30, 2023, we generated revenue of $478,942 and our costs of revenue were $254,648. Our revenue for April 30, 2024, was derived from sales from contract manufacturing services performed in our Pocono Pharmaceuticals (Active Intelligence) segment $-0- from contract research and development services from our 4P Therapeutics segment. The revenue from the Transdermal Patches segment remained relatively constant from the prior year. An increase in demand is expected in the balance of the current year. The Company’s contract with Sorrento Therapeutics was completed and 4P Therapeutics devoted most of its time to the development of its Aversa product, our cost of revenue for our contract research and development services represents our labor cost plus a modest amount of material costs which we passed on to the client.